Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Sikkerhet og effektivitetsevaluering av iCover-dekket stent for behandling av okklusive aorto-iliaca-sykdom (iliCo)

3. november 2026 oppdatert av: iVascular S.L.U.

Prospektiv, multisenter, ikke-randomisert, enarms observasjonsstudie for å evaluere sikkerhet og effektivitet av iCover-dekket stent for behandling av den okklusive aorto-iliaca-sykdommen

The objective of this prospective, multi-center, non-randomized, single-arm observational study is to evaluate the safety and the efficacy of the iCover covered stent over a 24-month follow-up period for the treatment of de novo iliac occlusive lesions, defined by a significant vessel stenosis ≥70%, in patients with symptomatic arteriopathy of the lower limbs (Rutherford class 2 to 5).

Studieoversikt

Status

Fullført

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

This is a prospective, single-arm, multinational, and multicenter study conducted to evaluate the safety and efficacy of the iCover covered stent for the treatment of de novo iliac occlusive lesions (common and/or external iliac arteries) in patients with symptomatic lower limb arteriopathy. The primary endpoint of the study is primary patency, defined as the absence of restenosis in the target lesion over a 12-month follow-up period in patients who did not undergo a reintervention on the target lesion. Restenosis is defined as a reduction in the luminal diameter of more than 50%, assessed either by duplex ultrasound (considered as a peak systolic velocity index ≥ 2.4 at the target lesion) or by angio-CT (multiplanar reconstruction). Secondary endpoints include: technical and procedural success rate, freedom from all major adverse events, incidence of procedure- or device-related major local complications at the treated lesion, rate of SAEs, major amputation rate at the target limb, primary sustained clinical improvement (improvement in Rutherford classification), primary and secondary patency rates, TLR and TVR rates, and changes in ABI, the Walking Impairment Questionnaire, and the EQ-5D questionnaire from baseline.

Studietype

Observasjonsmessig

Registrering (Faktiske)

241

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

  • Belgia
      • Aalst, Belgia
        • Onze Lieve Vrouw Aalst
      • Bonheiden, Belgia
        • Imelda Bonheiden
      • Dendermonde, Belgia
        • Az Sint Blasius Dendermonde
      • Genk, Belgia
        • ZOL Genk
  • Frankrike
      • Brest, Frankrike
        • Centre Hospitalier Universitaire de Brest
      • Paris, Frankrike
        • Hôpital Paris Saint Joseph
      • Paris, Frankrike
        • CHU Pitié Salpêtrière
      • Pessac, Frankrike
        • Hôpital privé Saint-Martin
      • Villeneuve-d'Ascq, Frankrike
        • Hôpital privé Villeneuve d'Ascq
  • Spania
      • Barcelona, Spania
        • Hospital Universitari Germans Trias i Pujol
      • Barcelona, Spania
        • Hospital de Santa Creu i Sant Pau
      • Bilbao, Spania
        • Hospital de Cruces
      • Sabadell, Spania
        • Hospital Parc Taulí
  • Tyskland
      • Berlin, Tyskland
        • KEH Berlin
      • Rendsburg, Tyskland
        • Imland Klinik Rendsburg
    • Baden-Wurttemberg
      • Bad Krozingen, Baden-Wurttemberg, Tyskland, 79189
        • Herzzentrum Bad Krozingen
    • Rhineland-Palatinate
      • Kaiserslautern, Rhineland-Palatinate, Tyskland, 67657
        • MVZ Kaiserslautern
    • Saxony
      • Leipzig, Saxony, Tyskland, 04103
        • Universitätsklinikum Leipzig

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Patients with symptomatic arteriopathy of the lower limbs (Rutherford class 2 to 5). Patients with de novo atheromatous aorto-iliac lesions.

According to the incidence of TASC II lesions, approximately 70% of the patients will be classified as TASC II A or B lesions, while the other 30% will be classified as TASC II C or D lesions.

Beskrivelse

Inclusion criteria

  1. ≥ 18 years of age
  2. Rutherford clinical stage 2 to 5
  3. Significant (≥70%) stenosis of atheromatous iliac lesions evidenced by duplex scan, MRI CT angiography or arteriography
  4. De novo atheromatous lesion of the aortoiliac segment
  5. Patient informed about the study and collection of the patient's informed consent agreement Exclusion criteria

Subjects will not be eligible to participate in the study if any of the following conditions are present in the subject:

  1. Protected adult patients, guardianship, curatorship, safeguard of justice
  2. Woman with possibility of pregnancy
  3. Patient with asymptomatic atheromatous lesions
  4. Patient with inflow lesion in the infrarenal aorta
  5. Patient treated with Covered endovascular reconstruction of aortic bifurcation (CERAB reconstruction)
  6. Acute ischemia or acute thrombosis
  7. Non-atherosclerotic disease
  8. History of coagulopathy
  9. Severe comorbidities with life expectancy <2 years
  10. Contraindication to taking antiplatelet aggregation therapy (aspirin or clopidogrel). The patient must be able to take an antiplatelet aggregation for at least 3 months after the procedure
  11. Patient participating in another clinical study which may interfere with the results
  12. Comorbidity or any reason which, according to the investigator, could limit the participation, the patient's adherence with the follow-up or the scientific integrity of the study
  13. Lesion near or adjacent to an aneurysm
  14. Inability to follow-up during the investigation
  15. Patient objection to participate in the investigation

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
iCover covered stent

Percutaneous transluminal angioplasty (PTA)
Enhet: Covered stent implantation

Percutaneous transluminal angioplasty (PTA) with iCover covered stent for the treatment of de novo aorto-iliac occlusive lesions

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Primary Patency
Tidsramme: 12 months after index procedure.

The primary patency, defined as the absence of restenosis in the target lesion over the 12-month follow-up period in patients who did not undergo a reintervention on the target lesion.
12 months after index procedure.

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Technical success rate
Tidsramme: Day 0.

Technical success rate, defined as the ability to cross and dilate the lesion and achieve residual angiographic stenosis no greater than 30% after iCover stent graft insertion. Outcomes will be computed as the percentage of lesions treated at the end of the procedure.
Day 0.
Procedural success rate
Tidsramme: Day 0.

Procedural success rate, defined as technical success and no complications during the procedure including general and local complications as defined in the protocol. Outcomes will be computed as the percentage of patients at the end of the procedure.
Day 0.
Freedom from All Major Adverse Event (MAEs)
Tidsramme: 1, 6, 12, 24 months after index procedure.

MAEs are described as All-Cause Mortality post-procedure, Target Lesion Revascularization (TLR) post-procedure and Major Amputation of the Target Limb post-procedure (amputations above the ankle of the target leg).
1, 6, 12, 24 months after index procedure.
Incidence of Procedure- or Device- related Major Local Complications
Tidsramme: Up to 30 days after index procedure.

Incidence of Procedure- or Device- related Major Local Complications at the treated lesion or Puncture Site up to 30 days post-procedure. Major Local Complications include: Iliac arterial rupture, retroperitoneal hematoma, thrombosis of the iliac axis on the ipsilateral side, need for surgery to achieve hemostasis, bleeding with loss of more than 2 g/ dL of hemoglobin, false aneurysm at the puncture site, preventing resumption of walking at 24 hours or appearance of ischemia on the ipsilateral side.
Up to 30 days after index procedure.
Rates of Serious Adverse Events (SAEs)
Tidsramme: 1, 6, 12, 24 months after index procedure.

Rates of SAEs, including both related and unrelated events. SAEs will be categorized as related or unrelated to the procedure/device based on adjudication by an Independent Clinical Events Committee.
1, 6, 12, 24 months after index procedure.
Major amputation at target limb rate
Tidsramme: 1, 6, 12, 24 months after index procedure.

Percentage of patients with amputations above the ankle of the target leg will be counted.
1, 6, 12, 24 months after index procedure.
Primary sustained clinical improvement
Tidsramme: 1, 6, 12, 24 months after index procedure.

Primary sustained clinical improvement defined as a sustained upward shift of 1 category of the Rutherford classification for patients with claudication, and by wound healing and rest pain resolution for patients in critical limb ischemia, without the need for repeated target lesion revascularization in surviving patients.
1, 6, 12, 24 months after index procedure.
Primary patency rates
Tidsramme: 6 and 24 months after index procedure.

Primary patency rates, defined as the lack of restenosis without reintervention of the target lesion. Restenosis is defined as a reduction in the luminal diameter of more than 50%, determined by either, duplex ultrasound examination considered as a peak systolic velocity index ≥ 2.4 at the target lesion, or by angio-CT (multiplanar reconstruction). In case of death, the vessel is considered as patent as long as no restenosis was detected during the last visit before the patient died. Outcomes will be computed as the percentage of lesions (Time frame: 6, 24 months after index procedure).
6 and 24 months after index procedure.
Secondary patency rates
Tidsramme: 6, 12, 24 months after index procedure.

Secondary patency rates, defined as the patency of the stent following an endovascular or surgical reintervention due to significant in-stent restenosis or occlusion. Outcomes computed as percentage of lesions.
6, 12, 24 months after index procedure.
Target lesion revascularization (TLR) rate
Tidsramme: 1, 6, 12, 24 months after index procedure.

Target lesion revascularization (TLR) rate, defined as the need for repeated procedures (endovascular or surgical) due to a problem arising from the lesion initially treated in surviving patients with preserved limbs. Outcomes will be computed as the percentage of lesions.
1, 6, 12, 24 months after index procedure.
Target vessel revascularization (TVR) rate
Tidsramme: 1, 6, 12, 24 months after index procedure.

Target vessel revascularization (TVR) rate, defined as the need for repeated procedures (endovascular or surgical) due to a problem arising remote from the vessel initially treated in surviving patients with preserved limbs. Outcomes will be computed as the percentage of lesions.
1, 6, 12, 24 months after index procedure.
Change in Ankle-Brachial Index (ABI) from baseline
Tidsramme: 1, 6, 12, 24 months post-procedure.

Change in ABI from baseline.
1, 6, 12, 24 months post-procedure.
Change in Walking Impairment Questionnaire from baseline
Tidsramme: 1, 6, 12, 24 months post-procedure.

The Walking Impairment Questionnaire values will be recorded and compared to the baseline values. This questionnaire is a validated tool to assess walking capability in patients with Peripheral Arterial Disease in different situations.
1, 6, 12, 24 months post-procedure.
Change in quality of life from baseline
Tidsramme: 1, 6, 12, 24 months post-procedure.

Change in quality of life from baseline, as measured by EQ-5D. The EQ-5D Questionnaire values will be recorded and compared to the baseline values. It is a validated questionnaire to measure the quality of life based on 5 different parameters. Worst possible score in this study would be 0, best possible score would be 1. In addition, the patient indicates her/his current health on an analog scale from 0 (worst) to 100 (best).
1, 6, 12, 24 months post-procedure.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

iVascular S.L.U.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

27. april 2022

Primær fullføring (Faktiske)

30. juni 2025

Studiet fullført (Faktiske)

30. september 2026

Datoer for studieregistrering

Først innsendt

14. desember 2021

Først innsendt som oppfylte QC-kriteriene

13. januar 2022

Først lagt ut (Faktiske)

14. januar 2022

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

5. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

3. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • iliCo Study

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere